

[Open Peer Review on Qeios](#)

# Gonadotropin-releasing Hormone Receptor Antagonist OBE2109

National Cancer Institute

## Source

National Cancer Institute. *Gonadotropin-releasing Hormone Receptor Antagonist OBE2109*. NCI Thesaurus. Code C148479.

An orally bioavailable gonadotropin-releasing hormone (GnRH or LHRH) receptor antagonist, with potential hormone production inhibitory activity. Upon oral administration of the GnRH receptor antagonist OBE2109, this agent competes with GnRH for receptor binding and inhibits GnRH receptor signaling in the anterior pituitary gland, thereby inhibiting the secretion and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone. As a result, this may relieve symptoms associated with hormonally dependent disease states such as hormone-dependent prostate cancer. In women, this prevents the production of estrogen by the ovaries and may relieve symptoms from sex-hormone dependent diseases, such as pain associated with endometriosis, heavy menstrual bleeding or uterine fibroids.